ArticleFrontiers in pain research (Lausanne, Switzerland)2026
Longitudinal predictor analysis of pain in breast cancer survivors on aromatase inhibitors-the PAC-WOMAN trial.
Article in Frontiers in pain research (Lausanne, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multidimensional Recovery Trajectories Throughout Breast Cancer Treatment and Survivorship: A Prospective Longitudinal Study.Current oncology (Toronto, Ont.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Breast cancer survivors undergoing hormonal therapy with aromatase inhibitors face a significantly increased risk of developing musculoskeletal pain, leading to treatment discontinuation rates of 13% to 22%. Recent literature has focused on identifying and understanding possible risk factors for pain development in breast cancer survivors, not only for pain prevention but also for guiding treatment strategies. This study aimed to investigate predictors of baseline, 4-month, and change scores of pain intensity in breast cancer survivors on aromatase inhibitors. Methods: Multiple regression analyses using intent-to-treat data ( Results: Having a partner (95% CI: 0.220, 1.868, Conclusions: These findings highlight the complex and multifaceted nature of pain in this population and the need for longitudinal studies with diverse populations, as well as advanced methodologies to capture the dynamic nature of pain and refine intervention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.